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Abstract
Background: Dexmedetomidine, an alpha2-adrenoceptor agonist, has been evaluated as an adjunct to anesthesia
and for the delivery of sedation and perioperative hemodynamic stability. It provokes dose-dependent and
centrally-mediated sympatholysis. Coronary artery bypass grafting (CABG) with extracorporeal circulation is a
stressful procedure increasing sympathetic nervous system activity which could attenuate renal function due the
interrelation of sympathetic nervous system, hemodynamics and renal function. We tested the hypothesis that
dexmetomidine would improve kidney function in patients undergoing elective CABG during the first two
postoperative days.
Methods: This was a double-blind, randomized, parallel-group study. Patients with normal renal function and
scheduled for elective CABG were randomized to placebo or to infusion of dexmedetomidine to achieve a pseudo
steady-state plasma concentration of 0.60 ng/ml. The infusion was started after anesthesia induction and continued
until 4 h after surgery. The primary endpoint was creatinine clearance. Other variables included urinary creatinine
and output, fractional sodium and potassium excretion, urinary potassium, sodium and glucose, serum and urinary
osmolality and plasma catecholamine concentrations. The data were analyzed with repeated-measures ANOVA or
Cochran-Mantel-Haenszel test.
Results: Sixty-six of 87 randomized patients were evaluable for analysis. No significant between-group differences
were recorded for any indices of renal function except for a mean 74% increase in urinary output with
dexmedetomidine in the first 4 h after insertion of a urinary catheter (p < 0.001). Confidence interval examination
revealed that the sample size was large enough for the no-difference statement for creatinine clearance.
Conclusions: Use of intravenous dexmedetomidine did not alter renal function in this cohort of relatively low-risk
elective CABG patients but was associated with an increase in urinary output.
This study was carried out in 1994-1997 and was thus not registered.
Background
Perioperative administration of alpha2-adrenergic agonist
dexmedetomidine, has been shown to reduce anesthetic
requirements, enhance hemodynamic stability and pro-
vide sedation during postoperative recovery following
coronary artery bypass and other surgery [1-6]. Acute
kidney injury (AKI) is a recognized complication of
cardiovascular surgery and one associated with high
mortality and costs-of-care [7]. The pathogenesis of AKI
is multifactorial and involves hemodynamic, inflamma-
tory and nephrotoxic components [7]. It is also known
that hemodynamics, sympathetic nervous system activity
and renal function are tightly interrelated. Since cardiac
surgery is associated with activation of sympathetic ner-
vous system [3], dexmedetomidine-induced sympatholy-
sis might attenuate harmful hemodynamic events
resulting in prevention of AKI. In fact, alpha2-adreno-
ceptor activation does produce some potentially renal-
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any medium, provided the original work is properly cited.protective effects including inhibition of renin release,
increased glomerular filtration and increased secretion
of sodium and water [8,9]. Moreover, pretreatment with
clonidine, the archetype of alpha2-adrenergic agonists,
has shown beneficial renal effects after cardiac surgery
[10]. In an earlier study we found that urine output
tended to be greater in patients receiving dexmedetomi-
dine than in those receiving placebo in post-coronary
artery bypass grafting (CABG) patients [3].
To date, no single pharmacological regimen has con-
clusively proved its efficacy in preventing AKI [7] and
any potential means to decrease the number of cardiac
surgery patients encountering this deleterious adverse
effect should be sought. We conducted a study to test
the hypothesis that dexmedetomidine could protect kid-
ney function in patients undergoing CABG with extra-
corporeal circulation (ECC). This study reports renal
effects of dexmedetomidine compared to placebo.
Methods
This was a double-blind, randomized, parallel-group
study designed to compare dexmedetomidine, adminis-
tered as a continuous intravenous (i.v.) infusion at rates
needed to achieve a pseudo steady-state plasma concen-
tration of 0.60 ng/ml, with placebo in terms of renal
effects. Altogether 93 patients were screened and 87
were randomized to receive the study treatment
(Figure 1) in two study centers, Helsinki and Turku
University Hospitals. Selection of the target concentra-
tion for dexmedetomidine was based on previous experi-
ence in CABG patients [3].
The study was performed according to Helsinki
Declaration and standards of Good Clinical Practise.
The protocol and amendments were reviewed and
approved by separate Ethics Committees of Turku and
Helsinki Universities and the Finnish Medicines Agency.
All patients provided written informed consent. Adult
(aged > 21 years) patients undergoing scheduled elective
CABG surgery at the two study centers were candidates
for inclusion in the study if they had normal renal func-
tion and serum creatinine (S-Crea) < 115 μmol/l, were
of American Society of Anesthesiologists (ASA) physical
status III or IV, and met the general participation cri-
teria for the study. Patients were not admitted to the
study if they had left main coronary artery occlusion >
50%, valvular dysfunction necessitating operation, hemo-
dynamically significant arrhythmia, or left ventricular
ejection fraction < 40%. Other exclusion conditions
included: treatment with angiotensin-converting enzyme
inhibitors or diuretics; use of alpha2-agonists to treat
Figure 1 Summary of patient disposition.
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disease; type 1 diabetes mellitus or diabetes insipidus;
morbid obesity; evidence or suspicion of abnormal liver
function due to drug abuse or alcoholism; a history of
severe allergy to drugs; and previous exposure to dex-
medetomidine. Pregnant or breastfeeding women were
ineligible, as were women of childbearing age not using
reliable contraceptive methods. Randomization was per-
formed by an independent statistician using random
permuted blocks of 10 patients within each center. Both
centers were provided with indistinguishable ampoules
of dexmedetomidine and placebo to be allotted in
numerical order to consecutive patients enrolled by
study physicians. All patients, personnel and investiga-
tors including the persons responsible for data manage-
ment and statistics were blinded to the treatment
assignment. The code was opened only after recruitment
and data collection of all study patients had been
completed.
Study outline and measurements
All patients received zopiclone 7.5 mg orally the night
before surgery. Oral lorazepam 4-6 mg was administered
2 h before induction of anesthesia.
Patients were instrumented upon arrival in the operat-
ing theater, including the introduction of a pulmonary
artery catheter. Ringer’s acetate was infused intrave-
nously at 10 ml · kg
-1 ·h
-1 until commencement of
ECC. Baseline hemodynamic and blood chemistry mea-
surements were obtained after at least 5 min of stabilisa-
tion after catheterisation. Anesthesia was induced with
30 μg / k gf e n t a n y lg i v e na sa5 - m i ni . v .i n f u s i o na n dc o -
administered with i.v. lorazepam 2 mg. Pancuronium 0.1
mg/kg was then administered i.v. and a urinary catheter
introduced. All urine passed during the 48 h after cathe-
ter insertion was collected.
Study drug infusion was commenced immediately
after anesthesia induction, and continued until 4 h after
arrival in the intensive care unit (ICU). To reach and
maintain a constant pseudo steady-state plasma concen-
tration of 0.60 ng/ml of dexmedetomidine a five-step
infusion of 4.0 μg/ml dexmedetomidine or placebo with
the following decreasing infusion rates was used: 39.0
ml/h for 20 min, 24.5 ml/h for 40 min, 14.0 ml/h for 60
min, 10.5 ml/h 120 min and 7.0 ml/h from that on. The
dosing was based on our previous experience with dex-
medetomidine in CABG patients [3] and simulation
with data available from Talke et al. [11].
CABG was performed under ECC using moderate sys-
temic hypothermia (nasopharyngeal temperature 30°C),
a standardized protocol and mannitol 150 mg/ml 100
ml added to ECC priming. ECC was initiated at a flow
rate of 2.4 l min
-1 ·m
-2 and reduced to 1.8 l min
-1 ·m
-2
during hypothermia. Cold crystalloid potassium
cardioplegic solution was used as required to maintain
asystole.
Intraprocedural anaesthesia was maintained with fen-
tanyl 0.1 μg·k g
-1 ·m i n
-1 until rewarming (rectal tem-
perature 35°C). Isoflurane was administered into the
perfusion unit at an inspiratory concentration of 0.2%.
Patients were ventilated with 40-60% oxygen in air with
at a r g e ta r t e r i a lC O 2 tension of 35-45 mmHg (not cor-
rected to the patient’s temperature) and oxygen satura-
tion (SaO2) > 95%. Fentanyl and isoflurane were
discontinued after skin closure.
Cardiovascular parameters and clinical signs were used
as indicators of anesthetic depth. Specific provisions and
interventions were developed in the study protocol to
maintain a sufficient level of anesthesia and acceptable
hemodynamics, to prevent tachycardia, bradycardia,
hypertension or hypotension lasting 1 min or more and
manage low urinary output intraoperatively and post-
operatively. These criteria and the respective therapeutic
interventions are summarized in table 1. Deviations in
other hemodynamic parameters were dealt with as a
part of standard clinical practice. Post-CABG, patients
were transferred to the ICU, where they were ventilated
and weaned from respirator according to standard ICU
protocols.
Creatinine clearance
The primary endpoint of the study was renal function
assessed by determination of creatinine clearance at 12-
24 h prior to surgery, and 0-24 h and 24-48 after urin-
ary catheter insertion after induction of anesthesia.
Creatinine clearance was defined as (U-Crea) × (urine
output)/S-Crea, where U-Crea and S-Crea represent
urinary and serum creatinine, respectively.
Other variables of renal function
Creatinine clearance from 30 min urine output at 4-h
intervals was quantified. Cumulative and 4-hourly urin-
ary output was examined. Fractional sodium excretion
(dU-Na) and fractional potassium excretion (dU-K) were
determined at the same time as creatinine clearance.
Urine samples for determination of urinary potassium
(U-K), urinary sodium (U-Na), U-Crea, urinary glucose
(U-Gluc) and urinary osmolality (U-Osmol) were taken
after urinary catheter insertion, 1 min after aortic cross
clamp removal and 24 and 48 h after urinary catheter
insertion. In addition samples for determination of U-
Na and U-Crea were taken at 4 h intervals until 24 h
from catheter insertion.
Plasma cathecolamines
Plasma epinephrine and norepinephrine concentrations
were determined using high-performance liquid chroma-
tography with coulometric detection [12].
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Forty patients per treatment group were needed to get a
80% power to detect a 35% difference between the treat-
ment groups with a 5% (two-sided) type I error rate and
assuming a standardized effect size (expected effect size
divided by SD of the outcome variable) of 0.63. Assum-
ing a 10% drop-out rate, the final sample size was set at
88 patients (44/group).
Table 1 Protocol-specified intraoperative and postoperative interventions for maintenance of hemodynamic and
anesthetic stability, and correction of low urinary output
Tachycardia*
Before ECC HR > 90 beats/min Esmolol in increments of 0.5 mg/kg i.v.
After ECC HR > 110 beats/min As above
In the ICU HR > 120 beats/min Esmolol 0.5 mg/kg i.v. If HR decreased < 120 beats/min, give
metoprolol 1-5 mg i.v.
Bradycardia
Before ECC HR < 40 beats/min Glycopyrrolate 0.2 mg i.v.
After ECC HR < 70 beats/min As above
In the ICU HR < 60 beats/min Pacing at 70 beats/min
Hypertension**
Before ECC SAP > 150 mmHg Increase ET-IF by 0.4% and administer 50 μg i.v. bolus of glyceryl
trinitrate. If response not adequate within 4 min, increase ET-IF a
further 0.4% and give 5 μg/kg i.v. bolus of fentanyl. If still not adequate,
increase ET-IF by 0.4% and give 50 μg i.v. bolus of glyceryl trinitrate.
Taper isoflurane (to 0.2% ET-IF) when SAP and HR have reached
predetermined values with no clinical signs of insufficient anaesthesia.
If SAP or HR rises again, increase ET-IF by 0.4% and give 50 μg i.v.
glyceryl trinitrate.
During ECC MAP > 80 mmHg As above
After ECC SAP > 130 mmHg As above
In the ICU SAP > 150 mmHg Start glyceryl trinitrate infusion to effect.
Hypotension
Before ECC SAP < 90 mmHg Reduce ET-IF 0.4% per 4 min until ET-IF 0.2%. If not sufficient to restore
SAP, administer ephedrine 2.5 mg i.v. bolus. If SAP response still not
adequate repeat ephedrine bolus plus 250 ml i.v. bolus of
hydroxyethylstarch (or 500 ml of Ringer’s acetate).
If necessary, repeat this intervention once, 4 min after first
administration. If SAP response still not adequate, start epinephrine
infusion at 0.03 μg · kg-1 · min-1; titrate to maximum of 0.3 μg · kg-1 ·
h-1. Taper epinephrine when SAP remains within protocol-specified
values.
During ECC MAP < 30 mmHg i.v. bolus doses of phenylephrine (0.2 mg)
After ECC SAP < 80 mmHg As for ‘Before ECC’
In the ICU SAP < 90 mmHg 250 ml i.v. bolus of hydroxyethylstarch (or 500 ml of Ringer’s acetate)
over 10 min. If effective, repeat. Otherwise start epinephrine at a rate of
3 μg · kg-1 · min-1
Clinical signs of
light anaesthesia
E.g. bucking, lacrimation, sweating, movement, eye
opening, grimacing
As for management of hypertension
Low urinary output
Before ECC Urinary output < 1 ml · kg-1 · h-1 during a 30 min
period, when SAP above threshold for hypotension
250 ml i.v. bolus of hydroxyethylstarch (or 500 ml of Ringer’s acetate)
over 10 min. If response not sufficient, repeat twice.
If response not sufficient 15 min after third bolus, administer
furosemide 5 mg i.v. every 30 min until effect is produced
During ECC Urinary output < 1 ml · kg-1 · h-1 during a 30 min
period, MAP > 30 mmHg
Phenylephrine 0.2 mg i.v. bolus dose, repeated up to 3 times until MAP
≥ 50 mmHg.
If urinary response not sufficient despite MAP ≥ 50 mmHg for 30 min,
administer furosemide 5 mg i.v. every 30 min until effect is produced
After ECC As for ‘Before ECC’ As for ‘Before ECC’
In the ICU Urinary output < 1 ml · kg-1 · h-1 250 ml i.v. bolus of hydroxyethylstarch (or 500 ml of Ringer’s acetate)
over 10 min. If response not sufficient, give furosemide 5 mg i.v. at 30
min intervals
*Without hypertension; **with or without tachycardia or clinical signs of inadequate anaesthesia. ECC = extracorporeal circulation; HR = heart rate;
ET-IF = end-tidal concentration of isoflurane; ICU = intensive care unit, MAP = mean arterial pressure; SAP = systolic arterial pressure.
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meeting the following five criteria of evaluation: (i)
study drug infusion commenced within 30 min after
anesthesia induction and continued intraoperatively and
2-4 h postoperatively; (ii) preoperative and one other
perioperative 24 h creatinine clearance value obtained;
(iii) no reoperation during the study period; (iv) no
development of myocardial dysfunction requiring ino-
tropes or intra-aortic balloon pump support; and (v)
extubation within 24 h post-CABG. A supplementary
analysis of creatinine clearance was also carried out,
based on the intention-to-treat (ITT) population of 87
patients.
Creatinine clearance was analyzed using repeated-
measures ANOVA with treatment and center as group-
ing factors and time as a within factor. Perioperative
dU-Na, total and cumulative urine volume, S-Crea, U-
Crea, serum and urinary electrolytes (serum potassium
[S-K], serum sodium [S-Na], urinary potassium [U-K],
urinary sodium [U-Na serum and urinary osmolarity (S-
Osmol, U-Osmol) and blood glucose were examined in
a similar way. The Cochran-Mantel-Haenszel (CMH)
test was used for urinary glucose, requirement, plasma
catecholamines and requirements for postoperative car-
diac pacing.
Results
The study was carried out in years 1994-1997 and pre-
maturely terminated due to slow recruitment rate
towards the end of the study. After opening the study
code it turned out that a total of 93 Caucasian patients
had been screened for eligibility, of which 87 had been
randomized: 44 to receive dexmedetomidine and 43 to
receive placebo. Twenty-one of the randomized patients
(dexmedetomidine, n = 9; placebo, n = 12) did not fulfill
the evaluation criteria. Analysis of creatinine clearance
was thus based on 66 evaluable patients (dexmedetomi-
dine, n = 35; placebo, n = 31). The disposition of
patients is illustrated in figure 1.
Table 2 summarizes demographic and other baseline
characteristics of the evaluable patients (n = 66) in the
two study groups. There were no significant differences
between the groups regarding concurrent and preopera-
tive cardiac medications, baseline laboratory data, dura-
tion of anesthesia during CABG, time to extubation or
duration of study drug infusion. Mean artery pressure
(MAP) was 86 ± 9 mmHg in the dexmedetomidine
group and 82 ± 8 mmHg in the placebo group (p =
0.015) prior to ECC. During ECC MAP was 55 ± 7
mmHg and 58 ± 8 mmHg (p = 0.064) in dexmedetomi-
dine and placebo groups, respectively. After ECC until
admission to ICU MAP was 68 ± 6 mmHg in the dex-
medetomidine group and 73 ± 9 mmHg (p = 0.019) in
the placebo group. Postoperatively systolic blood
pressure was measured instead of MAP up to 24 h from
admission to ICU being 109 ± 10 mmHg and 111 ± 10
mmHg (p = 0.44) in dexmedetomidine and placebo
groups, respectively. The total volume of intraoperative
Ringer’s acetate administered was 5215 ± 913 ml in the
dexmedetomidine group and 4996 ± 1105 ml (p = 0.21)
in the placebo group. The postoperative volumes of
Ringer’s acetate in the ICU up to 24 h from urinary
catheter insertion were 2942 ± 1084 ml and 2958 ±
1037 ml (p = 0.41) in dexmedetomidine and placebo
groups, respectively. The intraoperative hydroxyethyl
starch volumes were 344 ± 309 ml and 419 ± 440 ml (p
= 0.97) and postoperatively 1064 ± 385 ml and 968 ±
451 ml (p = 0.47) in dexmedetomidine and placebo
groups, respectively. The average blood loss during the
first 16 h after CABG was 1104 ± 376 ml with dexme-
detomidine and 904 ± 307 ml with placebo (p = 0.023).
Twenty-five patients in both groups needed postopera-
tive defibrillation, equating to 71% of dexmedetomidine-
treated patients and 81% of patients in the placebo
group (p = 0.56 for overall comparison between groups).
Eighteen dexmedetomidine patients and eight placebo
patients needed postoperative pacing (p = 0.028). As
this study focuses on the renal effects of dexmedetomi-
dine and hemodynamics were strictly guided by the
study protocol (Table 1), hemodynamics are not
reported.
Table 2 Patient demographics, operation data and
baseline hemodynamics
Dexmedetomidine
(n = 35)
Placebo
(n = 31)
Men 31 28
Women 4 3
Age (years) 59.5 ± 8.5 62.4 ± 7.0
Weight (kg) 83.7 ± 11.9 79.7 ± 8.7
Body surface area (m
2) 1.97 ± 0.17 1.92 ± 0.11
Systolic blood pressure (mmHg) 142 ± 21 138 ± 21
Diastolic blood pressure (mmHg) 73 ± 11 71 ± 9
Heart rate (beats/min) 61 ± 13 60 ± 7
ASA grade
III 2 0
IV 33 31
NYHA classification
II 12 12
III 22 17
IV 1 2
Operation time (min) 213 ± 55 190 ± 38
Perfusion time (min) 107 ± 29 96 ± 22
Number of grafts 3 ± 0.7 3 ± 0.6
Time to extubation (min) 1114 ± 248 1193 ± 283
Data are presented as number of subjects or mean ± SD. Data are based on
the per-protocol cohort (n = 66). ASA = American Society of Anesthesiologists;
NYHA = New York Heart Association.
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Perioperative creatinine clearance increased in both
groups during the study period (0-24-48 h), with a sig-
nificant time effect (p < 0.001) but without significant
difference between the groups (p = 0.93) (Figure 2).
Mean maximal increases were 15.2% and 26.2% in the
dexmedetomidine and placebo groups, respectively, with
no significant difference between groups. The 95% con-
fidence intervals (CIs) for group differences were from
-16.80 to 7.86 ml · min
-1 ·1 . 7 3m
-2 in the first 24 h
after catheter insertion and from -11.34 to 13.44 ml ·
min
-1 ·1 . 7 3m
-2 in the second 24 h (i.e. 24-48 h after
catheter insertion). Analysis based on ITT population
revealed that perioperative creatinine clearance (0-24-48
h) increased in both groups similarly to evaluable
patients with a significant time effect (p < 0.001). There
was no significant difference between the groups (p =
0.77). Mean maximal increases were 12.4% and 20.4% in
the dexmedetomidine and placebo groups, respectively,
with no significant difference between groups. The 95%
CIs for differences between the treatment groups were
from -15.28 to 8.88 ml · min
-1 ·1 . 7 3m
-2 in the first 24
h after catheter insertion and from -9.05 to 15.38 ml ·
min
-1 · 1.73 m
-2 24-48 h after catheter insertion.
Other variables of renal function
There was no significant intergroup difference in creati-
nine clearance calculated at 4-h intervals (Figure 3A).
Mean urinary output per 24 h increased from 1408 ±
623 ml before surgery to 5599 ± 1386 ml during the 24
h following catheter insertion in the dexmedetomidine
group and from 1314 ± 487 ml to 4497 ± 840 ml in the
placebo group (p < 0.001 between groups). Urinary
volumes 24-48 h after catheter insertion were 2799 ±
757 ml and 2938 ± 1037 ml, respectively (p = 0.67). Fur-
osemide was administered according to the conditions
specified in the protocol to stimulate urine production
in 22 dexmedetomidine-treated patients and 23 placebo-
treated patients (p = 0.32). The median dose was 5 mg
in both groups. Urinary output was also analyzed at 4-h
intervals. In paired comparisons, the urinary outputs in
the first (0-4 h) and third (8-12 h) fractions were signifi-
cantly higher in the dexmedetomidine group when com-
pared to placebo (p < 0.05). The mean urinary output in
the first fraction was 74% greater in the dexmedetomi-
dine group (Figure 3B; p < 0.001 vs. placebo). Fractional
sodium excretion increased several-fold in both groups
during and after surgery (Figure 3D).
Perioperative S-K and S-Na values were quite similar
in both groups. Dexmedetomidine patients had slightly
higher serum electrolyte levels towards the end of fol-
low-up (treatment-time interactions; p = 0.0045 for S-K;
p<0 . 0 0 1f o rS - N a )w i t h o u tt h ee f f e c to ft i m eo rt r e a t -
ment. Likewise, no treatment effect or effect of time in
the ANOVA was noticed, but there was a treatment-
time interaction for U-K (p = 0.0027). No effect of time,
treatment or treatment-time interaction for U-Na was
found. There was also a treatment effect on U-K (p =
0.0027 dexmedetomidine vs. placebo) at 48 h after
catheter removal but not at earlier times.
Perioperative S-Crea was relatively stable, with no sig-
nificant differences between the groups (Figure 3C). U-
Crea first fell by > 80% from baseline in both groups
thereafter gradually recovering with an overall time
effect (p < 0.001). There were no overall treatment effect
between the groups in S-Osmol and U-osmol (Table 3).
Time-dependent changes in blood and urine concentra-
tions of glucose were seen in both groups (p < 0.001).
Plasma catecholamines
CMH test showed a significant difference between the
groups in perioperative epinephrine concentrations (p <
0.001) although the concentrations were quite similar in
both treatment groups (Figure 4). Plasma norepinephr-
ine concentrations were significantly smaller in the dex-
medetomidine-treated patients (p < 0.001; Figure 4).
Discussion
Although urinary output increased and plasma norepi-
nephrine decreased in these relatively low-risk elective
CABG patients during dexmedetomidine treatment, we
were not able to demonstrate a significant dexmedeto-
midine-related benefit in terms of renal function as eval-
uated with creatinine clearance. In spite of the fact that
Figure 2 Perioperative creatinine clearance during the period
in the per-protocol cohort (primary efficacy endpoint). Data are
expressed as mean ± SD. P < 0.001 for time-trend in both groups;
no significant differences between the groups.
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reached, the confidence intervals for group differences
in creatinine clearance clearly demonstrate that our
sample size was adequate for a negative (no difference)
conclusion. Because of smaller than anticipated variance
in the primary endpoint, we can exclude a larger than
15% difference between the groups. We argue that such
a small difference would hardly have clinical signifi-
cance. It should also be noted that the protocol stipu-
lated the attainment and maintenance of a
dexmedetomidine plasma level of 0.6 ng/ml, which is at
the lower end of the preferred therapeutic concentration
Figure 3 Perioperative renal parameters. Creatinine clearance (A) and urinary output (B) in 4-h episodes. Serum creatinine (C) and fractional
sodium excretion (D) during the perioperative period. Data are expressed as mean ± SD. CCR = cross clamp removal.
Table 3 Serum and urine osmolality
Dexmedetomidine Placebo
S-Osmol mosm/kg U-Osmol mosm/kg S-Osmol mosm/kg U-Osmol mosm/kg
5 min after cannulation 291 ± 4 583 ± 178 292 ± 4 625 ± 152
1 min after cross clamp removal 295 ± 4 326 ± 93 293 ± 5 353 ± 80
24 h after urinary catheter insertion 296 ± 9 618 ± 117 290 ± 7 649 ± 85
48 h after urinary catheter insertion 294 ± 7 579 ± 128 295 ± 19 506 ± 84
There were no significant differences between the groups, effect of time or treatment-time interaction in serum osmolality (S-Osmol). Urine osmolality (U-Osmol)
initially decreased in both groups (p < 0.001 for time effect) without treatment effect. However, there was a significant treatment-time interaction in the ANOVA
(p = 0.024) and in paired comparisons dexmedetomidine patients had significantly higher values 48 h after urinary catheter insertion (p = 0.02)
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dual plasma concentrations nor did we consider the true
body weight of the patients in dose calculation. Thus,
there has likely been some interindividual differences in
the true plasma concentrations. Further trials may be
warranted to examine the effect of higher and weight-
based dexmedetomidine dosing on indices of renal func-
tion in higher risk patients.
Postoperative AKI is a relatively rare complication of
CABG but has a profoundly disadvantageous impact on
short-term (< 30 day) prognosis. In-hospital mortality
rates of 40% and more have been reported in several
series of patients, compared with rates of around 1% in
patients without kidney insufficiency [14-17]. Loef et al.
[17] have also reported a more than 10-fold increase in
short-term mortality with postoperative kidney insuffi-
ciency and, in contrast to some other investigators
[18,19], have linked postoperative AKI to reduced
longer-term survival. A recent review endorses the con-
tribution of AKI as an independent factor associated
with substantial morbidity and mortality following cardi-
opulmonary bypass [7].
In the present study, creatinine clearance was deter-
mined by direct measurement. We are supportive of
assertion of Holzmann and colleaques that indices of
clearance may be preferable to serum creatinine levels
as an indicator of renal function [20]. Others have advo-
cated markers such as cystatin C as an alternative
means of monitoring renal function [21]. Estimation of
glomerular filtration rate might also be considered as it
is part of the proposed RIFLE (risk, injury, failure, loss
and end stage kidney disease) classification for determi-
nation of AKI [22]. We can state that according to urin-
a r yo u t p u ta n ds e r u mc r e a t i n i n e ,t h e r ew e r en op a t i e n t s
fulfilling the definition of AKI according to RIFLE in the
present study.
Renal effects of alpha2-adrenergic agonists in clinical
settings have not been studied thoroughly so far. Pre-
treatment with the archetypal alpha2-adrenergic ago-
nists, clonidine, has shown preventive effects of renal
function expressed as creatinine clearance after cardiac
surgery [10]. Nevertheless, clonidine is a less selective
alpha2-adrenergic agonist than dexmedetomidine and
has somewhat different pharmacodynamic profile [1].
Attenuated response of sympathetic nervous system to
CABG has been suggested as a potential benefit of
alpha2-adrenergic agonists. Our results regarding norepi-
nephrine support this assumption as plasma norepi-
nephrine was reduced at various time points during the
study. However, these indications of reduced sympa-
thetic activity might have also an influence on the
greater blood loss in the dexmedetomidine group com-
pared to the placebo group, since high adrenergic out-
put favours thrombosis. On the other hand, the
relatively low number of patients and the nature of the
surgery might also predispose evaluation of blood loss
to type I error. More postoperative pacing was needed
in dexmedetomidine group which most probably is
Figure 4 Plasma epinephrine and norepinephrine concentrations during the perioperative period. Data are expressed as mean ± SD.
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cardiac conduction times [23].
The enhancement of urinary output with dexmedeto-
midine during the first 24 h after catheter insertion is
favourable for dexmedetomidine, though it does not
necessarily indicate a preserved renal function. Never-
theless, there was an increase of creatinine clearance
f r o mb a s e l i n ei nb o t hg r o u p sa n dt h ei n c r e a s ew a s1 1 %
higher in the placebo group, though this difference did
not reach statistical significance. The increase seen in
both treatment groups in creatinine clearance might
have been an artifact resulting from diurnal variation
[24], as baseline creatinine clearance was usually deter-
mined from 12-h night time urine samples rather than
from a 24-h sample. Eventual problems in spontaneous
voiding might also have resulted in systematic but likely
similar underestimation of baseline creatinine clearance
in both groups. Increased urine output is a recognized
property of dexmedetomidine and demonstrated already
earlier in patients undergoing CABG by us [3] and more
recently by others in patients undergoing thoracotomy
[25]. The diuretic action of dexmedetomidine evident
also in the present study is consistent with sympatholy-
sis-attenuated sodium reabsorption in tubular cells via
alpha2-adrenergic action [26]. We did not however, con-
trol or record fluid administration at the regular ward
during the second postoperative day. This may have
added irregularities in individual fluid management and
thus urine output during that period.
The fact that we included patients at a relatively low
risk of AKI may limit the interpretation of the results.
In addition, we had a high drop-out rate of 21 patients
due to the complexity of the study protocol. Neverthe-
less, all patients were included in the ITT analyses for
the main end-point which were essentially the same as
the per-protocol analyses.
Conclusions
This study showed that the use of intravenous dexmede-
tomidine did not alter renal function in this cohort of
relatively low-risk elective CABG patients although it
was associated with an increase in urinary output as
compared to placebo. Further trials are warranted to
elucidate the effect of dexmedetomidine in high-risk
patients.
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